|Bid||179.51 x 800|
|Ask||179.80 x 900|
|Day's range||179.66 - 179.77|
|52-week range||111.75 - 189.99|
|Beta (5Y monthly)||0.35|
|PE ratio (TTM)||N/A|
|Earnings date||23 Feb 2022 - 28 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||154.50|
In September, Merck (NYSE: MRK) announced plans to acquire Acceleron Pharma (NASDAQ: XLRN) for $11.5 billion. In this Motley Fool Live video recorded on Nov. 3, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss why Merck's move doesn't mean that the acquisition of Acceleron is in trouble.
NEW YORK, November 09, 2021--Avoro Capital Advisors ("Avoro"), a long-term and collaborative investor in life sciences and biotechnology companies, together with certain of its affiliates and managed funds ("Avoro," "we" or "us") beneficially owns approximately 7% of Acceleron Pharma Inc. (Nasdaq: XLRN) ("Acceleron", "XLRN" or the "Company"), making Avoro one of the Company's most significant shareholders. Avoro today released a detailed presentation outlining why shareholders should not tender
Acceleron (XLRN) delivered earnings and revenue surprises of 1.04% and -6.62%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?